[Edaily Reporter Kim Hyung-il ] As global investor interest in hair loss treatments continues, JW SHINYAK CORPORATION(067290)is posting double-digit gains in early trading.

According to MP Doctor on the 7th, JW SHINYAK CORPORATION is trading at 3,630 won on the KOSDAQ market as of 10:12 a.m., up 365 won (11.18%) from the previous trading day. In early trading, the stock rose by more than 15% to as high as 3,765 won.

Buying momentum continues to flow into related stocks as hair loss treatments have recently emerged as a new investment theme, following the trend of obesity treatments. Previously, on the 29th of last month, Bloomberg reported that companies developing new hair loss treatments are emerging as new investment targets on Wall Street, following GLP-1-class obesity treatments such as Wegovy and Mounjaro.

In fact, U.S.-based hair loss treatment developer Veradermix has seen its stock price rise by approximately 500% since its initial public offering (IPO) last February, and Appcy, which develops hair loss treatments using artificial intelligence (AI), is reported to have more than doubled in stock price this year. This global investment interest is believed to be spilling over into the domestic stock market, driving interest in hair loss treatment-related stocks.

JW SHINYAK CORPORATION is a pharmaceutical company affiliated with the JW Group that sells prescription drugs primarily to hospitals, clinics, and pharmacies. Among its hair loss treatments, the company offers the oral finasteride-based “Monad Tablets” and “Monasta Tablets,” as well as the dutasteride-based “Dutamoa Tablets.” Last year, it expanded its hair loss treatment portfolio by launching “Mydil 5% Foam Aerosol,” an over-the-counter topical medication containing 5% minoxidil.

Its affiliate, JWPHARMACEUTICAL, is also developing a new hair loss treatment. JWPHARMACEUTICAL is currently conducting a Phase 1 clinical trial for its new hair loss drug candidate, “JW0061.” JW0061 is a drug candidate for treating hair loss, and expectations regarding its future development outcomes are cited as a factor influencing the stock prices of related group companies.

JW SHINYAK CORPORATION’s stock price rally has continued since last week. Last week, it recorded the highest weekly gain among all KOSDAQ-listed stocks. Its stock price rose by 55.48% last week. After hitting the daily price limit on the 1st, the stock underwent a correction on the 4th but continued its upward trend, posting another double-digit gain on that day. Due to the sharp short-term surge, the Korea Exchange designated JW SHINYAK CORPORATION as a “stock requiring investor caution” on the 4th.